219763-83-4

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Chloro-6-cyanoquinoline is utilized as a key intermediate in the production of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of a wide range of medicinal compounds.
Used in Agrochemical Production:
In the agrochemical industry, 4-Chloro-6-cyanoquinoline serves as an essential intermediate for the synthesis of pesticides and other crop protection agents. Its incorporation aids in enhancing the effectiveness of these products in safeguarding crops from pests and diseases.
Used in Anti-Inflammatory Research:
4-Chloro-6-cyanoquinoline is employed as a subject of study in anti-inflammatory research, exploring its potential to alleviate inflammation and associated symptoms. Its properties are examined for possible incorporation into treatments for various inflammatory conditions.
Used in Antimicrobial Applications:
4-CHLORO-6-CYANOQUINOLINE is also being investigated for its antimicrobial capabilities, with potential use in the development of new antimicrobial agents to combat resistant bacteria and other pathogens. The research into its efficacy and safety is crucial for its application in this field.

Upstream product

• 873-74-5 4-Aminobenzonitrile 
• 557-21-1 zinc(II) cyanide 
• 40107-07-1 4-chloro-6-iodo-quinoline 
• 219763-81-2 4-[(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidenemethyl)-amino]-benzonitrile 
• 642477-81-4 4-Hydroxy-6-quinolinecarbonitrile 

Downstream Products

• 219763-87-8 4-bromoquinoline-6-carboxylic acid 
• 219763-85-6 4-bromoquinoline-6-carboxylic acid methyl ester 

Relevant academic research and scientific papers

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

IRAK INHIBITORS AND USES THEREOF

The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of IRAK enzymes.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.